Department of Otolaryngology-Head and Neck Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mol Carcinog. 2018 Mar;57(3):361-369. doi: 10.1002/mc.22760. Epub 2017 Nov 13.
Given the crucial role of Mouse double minute 4 (MDM4) oncoprotein in p53 pathway, single nucleotide polymorphisms (SNPs) could serve as such biomarkers for prediction of SCCOP recurrence. Thus, we investigated associations between three tagging putatively functional variants of MDM4, two in the 3' untranslated region of 3' UTR [rs11801299 (NC_000001.10:g.204529084G>A) and rs10900598(NC_000001.10:g.204525568G>T)] and one in intron 1 [rs1380576(NC_000001.10:g.204488278G>C)], and recurrence risk of SCCOP in 1,008 incident patients. A log-rank test and multivariable Cox models were used to assess associations. Patients with MDM4-rs10900598 GT/TT had a worse disease-free survival (DFS) compared with corresponding GG genotype, while those with rs11801299 AG/AA genotypes had a lower recurrence risk than the cases with rs11801299 GG genotype (both log-rank, P < 0.001). Multivariable analysis showed that significantly different recurrence risk were found among patients with MDM4-rs10900598 GT/TT and rs11801299 AG/AA variant genotypes (HR, 2.0, 95% CI, 1.4-2.9 and HR, 0.4, 95% CI, 0.3-0.6, respectively) compared with their corresponding common homozygous genotypes. Furthermore, after combining the risk genotypes of the three SNPs, patients among low-risk group had a significantly lower risk of SCCOP recurrence than those in high-risk group (HR, 0.2, 95% CI, 0.1-0.3). The risk for both individual SNPs or combined risk genotypes was restricted to HPV-positive SCCOP patients. Our findings suggest that the MDM4 polymorphisms may, individually or in combination, confer an independent risk of SCCOP recurrence, particularly in HPV-positive SCCOP patients. However, larger studies are needed to validate our findings.
鉴于鼠双微基因 4(MDM4)癌蛋白在 p53 通路中的关键作用,单核苷酸多态性(SNP)可以作为预测 SCCOP 复发的生物标志物。因此,我们研究了三个假定功能性 MDM4 标记变异与 3'UTR [rs11801299(NC_000001.10:g.204529084G>A)和 rs10900598(NC_000001.10:g.204525568G>T)]中的两个和内含子 1 [rs1380576(NC_000001.10:g.204488278G>C)]中的一个之间的关联,以及 1008 例新发病例患者的 SCCOP 复发风险。使用对数秩检验和多变量 Cox 模型评估关联。与相应的 GG 基因型相比,MDM4-rs10900598 GT/TT 患者的无病生存(DFS)较差,而 rs11801299 AG/AA 基因型的患者复发风险低于 rs11801299 GG 基因型的患者(均对数秩,P<0.001)。多变量分析显示,MDM4-rs10900598 GT/TT 和 rs11801299 AG/AA 变异基因型的患者复发风险显著不同(HR,2.0,95%CI,1.4-2.9 和 HR,0.4,95%CI,0.3-0.6)与相应的常见纯合基因型相比。此外,结合三个 SNP 的风险基因型后,低风险组的患者 SCCOP 复发风险明显低于高风险组(HR,0.2,95%CI,0.1-0.3)。个体 SNP 或组合风险基因型的风险仅限于 HPV 阳性 SCCOP 患者。我们的研究结果表明,MDM4 多态性可能单独或组合赋予 SCCOP 复发的独立风险,尤其是在 HPV 阳性 SCCOP 患者中。然而,需要更大的研究来验证我们的发现。